简 历      

白理惟是赛诺菲集团的首席执行官。  

白理惟具有专业医师背景，在全球医药行业拥有 28 年从业经验。他于 2015 年 4 月加入赛诺菲集团。加入 赛诺菲之前，白理惟于 2013 年至 2015 年担任拜耳医药保健集团首席执行官。任职期间，他负责领导公司在全 球的产品组合，涵盖处方药、消费者保健、动物保健和医疗护理业务。  

加入拜耳医药保健之前，白理惟在辉瑞公司工作了 13 年，最后担任的职位是执行管理团队成员，以及新 兴市场和成熟产品业务总裁兼总经理。他在辉瑞期间，还担任了一系列管理职位，包括于 2009 年至 2012 年担 任全球基础医疗事业部的负责人，于 2008 年至 2009 年担任全球特药事业部的负责人。他还曾领导了辉瑞在美 国的心脏病业务以及在全球数个地区的运营。  
白理惟在医药行业的职业生涯始于担任 Warner-Lambert/Parke-Davis 公司非洲区的医学总监，之后他又担 任了医学部和市场部的多个高级职位，以及加拿大分公司的总经理。他还在巴黎 Pitié -Salpêtrière 医院的传染 病和热带疾病研究所度过了八年，专注于西非和中非地区的疟疾研究，并在刚果共和国担任过两年医生。  

白理惟是美国药物研究及制造商（PhRMA）管理委员会的成员，也是国际药物制造商协会联盟（IFPMA） 的委员会成员。他同时担任伦敦皇家内科医学院的名誉成员，以及纽约儿童援助协会的董事会成员。  

白理惟曾在巴黎第五大学（即巴黎笛卡尔大学）学习传染病和热带疾病药物，获得细胞和免疫病理学的高 级学位。他还拥有巴黎第十二大学的生物学硕士学位。 

Olivier Brandicourt 

Olivier Brandicourt is the Chief Executive Officer (CEO) of Sanofi. 

A physician by training, Brandicourt has 28 years of global experience in the pharmaceutical industry. He joined Sanofi in April 2015 after serving as Chief Executive Officer of Bayer Healthcare AG since 2013. In this role, he was responsible for leading the company’s global portfolio across the pharmaceuticals, consumer care, animal health, and medical care businesses.  

Prior to Bayer Healthcare, Brandicourt worked at Pfizer for 13 years, where he most recently served as a member of the Executive Leadership Team and as President and General Manager of the Emerging Markets and Established Products business units. Over his career at Pfizer, he served in a series of leadership positions, including heading its Global Primary Care business unit from 2009 to 2012 and its Global Specialty Care business unit from 2008 to 2009. He also led its Cardiology business in the US, as well as several regional operations around the world.  

Brandicourt started his career as a Medical Director for the Region Africa at Warner-Lambert/ParkeDavis, where he held other senior positions in medical and marketing before being appointed General Manager of Canada. He also spent eight years with the Institute of Infectious and Tropical Diseases at the Pitié-Salpêtrière Hospital in Paris with a focus on malaria research in West and Central Africa and two years in the Republic of Congo as a doctor. 

He is a member of the Board of Management of the Pharmaceutical Research and Manufacturers of America (PhRMA), as well as a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). He is also an Honorary Member of the Royal College of Physicians in London and a board member of the Children’s Aid Society in New York. 

Olivier Brandicourt studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine (University of Paris V) and holds an Advanced Degree in Cellular and Immunological Pathophysiology from the Paris Descartes University. He also holds a Master’s Degree in Biology (University of Paris XII).